{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:49:21Z","timestamp":1790034561605,"version":"4.0.1"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Primary selective laser trabeculoplasty (SLT) is a safe primary treatment for open-angle glaucoma (OAG) and ocular hypertension (OHT). However, there is limited evidence on its use as a secondary treatment, ie, after prior use of ocular hypotensive eye drops.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate outcomes following SLT after using hypotensive eye drops for at least 3 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This is a post hoc exploratory analysis of data from a multicenter randomized clinical trial conducted within the UK National Health Service. Participants were patients with OAG or OHT who participated in the LiGHT trial. Data were analyzed from February 2021 to December 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Participants were initially randomized to either primary SLT or primary hypotensive eye drops and remained on the allocated treatment pathway for 3 years. Participants using eye drops were then allowed to have secondary SLT as a treatment switch (to reduce their medication load) or as a treatment escalation (if more intense treatment was needed). Participants were treated and monitored according to a predefined protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The outcomes of interest were rates of incisional glaucoma surgery, medication use, and intraocular pressure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 633 participants entered the extension of the LiGHT trial, and 524 participants (82.8%) completed the extension (72 months). Of 320 participants receiving primary hypotensive eye drops, 112 (35.0%) received SLT: 70 participants switched to SLT, 29 participants had SLT as a treatment escalation, and 13 participants had SLT as a treatment escalation in 1 eye and as a treatment switch in the other eye. Switching to SLT was associated with a reduction in the number of medications (mean [SD], 1.38 [0.62] to 0.59 [0.92] active ingredients; mean difference, 0.79 [95% CI 0.66 to 0.93] active ingredients; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). At 72 months, 69 eyes that switched to SLT (60.5%) needed no medical or surgical treatment, and 62 eyes receiving 1 drug before switching (83.8%) needed no medical treatment. Escalating to SLT was associated with a mean intraocular pressure reduction of 4.6 mm Hg (21.8%), and 30 eyes (62.5%) reached target intraocular pressure at 72 months without the need for surgery; 9 eyes (18.7%) needed a trabeculectomy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This secondary analysis of a randomized clinical trial found that secondary SLT was associated with a reduction in the medication load for stable, medically treated eyes. For medically uncontrolled eyes, there is evidence that SLT could provide additional intraocular pressure control, but the need for trabeculectomy was not eliminated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>isrctn.org Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN32038223\">ISRCTN32038223<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.6492","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:01:31Z","timestamp":1740067291000},"page":"295","source":"Crossref","is-referenced-by-count":8,"title":["Selective Laser Trabeculoplasty After Medical Treatment for Glaucoma or Ocular Hypertension"],"prefix":"10.1001","volume":"143","author":[{"given":"Evgenia","family":"Konstantakopoulou","sequence":"first","affiliation":[{"name":"NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom"},{"name":"Division of Optics and Optometry, University of West Attica, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gus","family":"Gazzard","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garway-Heath","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Adeleke","sequence":"additional","affiliation":[{"name":"Department of Statistical Science, University College London, London, United Kingdom"},{"name":"PRIMENT Clinical Trials Unit, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Ambler","sequence":"additional","affiliation":[{"name":"Department of Statistical Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Vickerstaff","sequence":"additional","affiliation":[{"name":"The Research Department of Primary Care and Population Health, University College London, London, United Kingdom"},{"name":"Marie Curie Palliative Care Research Department, UCL Division of Psychiatry, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[{"name":"Research Data and Statistics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom"},{"name":"London School of Hygiene & Tropical Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Nathwani","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Barton","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LiGHT Trial Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Bourne","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Broadway","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Buszewicz","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Crabb","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Davis","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Garg","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hornan","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Hunter","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Jayaram","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Jiang","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lim","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Liput","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Manners","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Montesano","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ometto","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Rubin","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Strouthidis","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wilson","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wormald","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wright","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haogang","family":"Zhu","sequence":"additional","affiliation":[{"name":"for the LiGHT Trial Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10180","key":"eoi240095r1","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","article-title":"Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial.","volume":"393","author":"Gazzard","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"eoi240095r2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","article-title":"LiGHT trial: 6-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension.","volume":"130","author":"Gazzard","year":"2023","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi240095r3","doi-asserted-by":"publisher","first-page":"e1589","DOI":"10.1016\/S2214-109X(21)00348-X","article-title":"Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial.","volume":"9","author":"Philippin","year":"2021","journal-title":"Lancet Glob Health"},{"key":"eoi240095r4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjophthalmol-2021-egsguidelines","article-title":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition.","volume":"105","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi240095r5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ophtha.2020.10.022","article-title":"Primary open-angle glaucoma preferred practice pattern.","volume":"128","author":"Gedde","year":"2021","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi240095r7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/IJG.0b013e3181e3d2c1","article-title":"SLT and adjunctive medical therapy: a prediction rule analysis.","volume":"20","author":"Martow","year":"2011","journal-title":"J Glaucoma"},{"issue":"3","key":"eoi240095r8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ajo.2005.02.047","article-title":"Selective laser trabeculoplasty as a replacement for medical therapy in open-angle glaucoma.","volume":"140","author":"Francis","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"eoi240095r9","first-page":"790","article-title":"Selective laser trabeculoplasty treatment for medication-refractory open angle glaucoma.","volume":"144","author":"Geyer","year":"2005","journal-title":"Harefuah"},{"issue":"9","key":"eoi240095r10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/bjophthalmol-2020-317117","article-title":"Clinical outcomes following selective laser trabeculoplasty in Afro-Caribbean patients with glaucoma at high risk for progression.","volume":"106","author":"Realini","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"eoi240095r11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/bjophthalmol-2017-310877","article-title":"Laser in Glaucoma and Ocular Hypertension (LiGHT) trial: a multicentre, randomised controlled trial: design and methodology.","volume":"102","author":"Gazzard","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"eoi240095r13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0008-4182(03)80060-1","article-title":"Canadian perspectives in glaucoma management: setting target intraocular pressure range.","volume":"38","author":"Damji","year":"2003","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"eoi240095r14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ajo.2005.07.044","article-title":"Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease.","volume":"141","author":"Mills","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"31","key":"eoi240095r18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta23310","article-title":"Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.","volume":"23","author":"Gazzard","year":"2019","journal-title":"Health Technol Assess"},{"key":"eoi240095r19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s13063-015-1047-9","article-title":"Statistical analysis plan for the laser-1st versus drops-1st for glaucoma and ocular hypertension trial (LiGHT): a multi-centre randomised controlled trial.","volume":"16","author":"Vickerstaff","year":"2015","journal-title":"Trials"},{"issue":"6","key":"eoi240095r20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ogla.2019.07.005","article-title":"Identifying outcomes that are important to patients with ocular hypertension or primary open-angle glaucoma: a qualitative interview study.","volume":"2","author":"Le","year":"2019","journal-title":"Ophthalmol Glaucoma"},{"issue":"16","key":"eoi240095r21","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1038\/s41433-023-02532-w","article-title":"Treatment expectations in glaucoma: what matters most to patients?","volume":"37","author":"Safitri","year":"2023","journal-title":"Eye (Lond)"},{"issue":"1","key":"eoi240095r22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41433-019-0656-z","article-title":"10-Year trends in English primary care glaucoma prescribing.","volume":"34","author":"Hogg","year":"2020","journal-title":"Eye (Lond)"},{"issue":"5","key":"eoi240095r23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ogla.2020.05.003","article-title":"Priorities and treatment preferences among surgery-naive patients with moderate to severe open-angle glaucoma.","volume":"3","author":"Bicket","year":"2020","journal-title":"Ophthalmol Glaucoma"},{"issue":"1","key":"eoi240095r24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ogla.2021.04.011","article-title":"The burden of caring for and treating glaucoma: the patient perspective.","volume":"5","author":"Stagg","year":"2022","journal-title":"Ophthalmol Glaucoma"},{"issue":"9","key":"eoi240095r25","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.ophtha.2019.04.012","article-title":"Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the Laser in Glaucoma and Ocular Hypertension Trial.","volume":"126","author":"Garg","year":"2019","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi240095r26","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"eoi240095r27","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery.","volume":"108","author":"Lichter","year":"2001","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi240095r28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"1014","key":"eoi240095r29","doi-asserted-by":"publisher","first-page":"n1014","DOI":"10.1136\/bmj.n1014","article-title":"Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS).","volume":"373","author":"King","year":"2021","journal-title":"BMJ"},{"key":"eoi240095r30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ajo.2022.09.011","article-title":"Two-year visual field outcomes of the Treatment of Advanced Glaucoma Study (TAGS).","volume":"246","author":"Montesano","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"eoi240095r31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajo.2021.06.012","article-title":"Long-term outcomes of selective laser trabeculoplasty for open-angle glaucoma in the Caribbean.","volume":"232","author":"Realini","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"eoi240095r32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jamaophthalmol.2024.3133","article-title":"Responsiveness to selective laser trabeculoplasty in open-angle glaucoma and ocular hypertension.","volume":"142","author":"Yang","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi240095r33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ophtha.2019.10.023","article-title":"Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT trial.","volume":"127","author":"Garg","year":"2020","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi240095r34","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.ophtha.2024.06.022","article-title":"The impact of baseline intraocular pressure on initial treatment response in the LiGHT Trial: selective laser trabeculoplasty versus medication.","volume":"131","author":"Fahy","year":"2024","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi240095r35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ophtha.2019.11.017","article-title":"Real-world outcomes of selective laser trabeculoplasty in the United Kingdom.","volume":"127","author":"Khawaja","year":"2020","journal-title":"Ophthalmology"},{"key":"eoi240095r16","volume-title":"Primary open-angle glaucoma: preferred practice pattern","author":"Glaucoma Preferred Practice Pattern Panel members","year":"2005"},{"key":"eoi240095r6","unstructured":"National Institute for Health and Care Excellence. Glaucoma: diagnosis and management. Accessed February 12, 2024. https:\/\/www.nice.org.uk\/guidance\/ng81"},{"key":"eoi240095r12","unstructured":"National Institute for Health and Clinical Excellence. NICE: Guidance on glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension. Accessed January 17, 2019. http:\/\/www.nice.org.uk\/CG85fullguideline"},{"key":"eoi240095r15","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma. Accessed February 27, 2019. https:\/\/www.eugs.org\/eng\/EGS_guidelines.asp"},{"key":"eoi240095r17","unstructured":"South East Asia Gluacoma Interest Group. Asia Pacific glaucoma guidelines. Accessed January 21, 2025. https:\/\/www.apglaucomasociety.org\/apgg-asia-pacific-glaucoma-guidelines"},{"key":"eoi240095r36","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. Accessed October 1, 2024. https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2830476\/jamaophthalmology_konstantakopoulou_2025_oi_240095_1743694211.75502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:01:46Z","timestamp":1744902106000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2830476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.6492","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}